Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges". Novo Nordisk launched the anti-obesity drug Wegovy, which uses the same molecule but has been directly approved as a weight loss treatment, in the United States in 2021.
